-+ 0.00%
-+ 0.00%
-+ 0.00%

MAIA Biotechnology To Initiate Phase 3 Pivotal Trial Of THIO Sequenced With Checkpoint Inhibitor Compared With Chemotherapy Treatment In Advanced Non-Small Cell Lung Cancer Patients; Phase 3 Trial Is Designed To Provide A Direct Comparison To Chemotherapy In A 1:1 Randomization Of Up To 300 Patients

Benzinga·02/27/2025 14:04:42
Listen to the news

MAIA Biotechnology, Inc., (NYSE:MAIA) ("MAIA", the "Company"), a clinical-stage biopharmaceutical company developing targeted immunotherapies for cancer, today announced plans to initiate a Phase 3 pivotal trial in 2025, named THIO-104, to evaluate the efficacy of THIO administered in sequence with a checkpoint inhibitor (CPI) in third-line non-small cell lung cancer (NSCLC) patients who are resistant to checkpoint inhibitors and chemotherapy. The multicenter, open-label, pivotal Phase 3 trial is designed to provide a direct comparison to chemotherapy in a 1:1 randomization of up to 300 patients.